Navigation Links
Horizon Technology Finance Closes $2 Million Venture Loan Facility with New Haven Pharmaceuticals
Date:4/25/2013

FARMINGTON, Conn. and GUILFORD, Conn., April 25, 2013 /PRNewswire/ -- Horizon Technology Finance Corporation (Nasdaq: HRZN) ("Horizon"), a leading specialty finance company that provides secured loans to venture capital and private equity backed development-stage companies in the technology, life science, healthcare information and services, and clean-tech industries, today announced it has closed a $2 million venture loan facility with New Haven Pharmaceuticals, Inc. ("NHP"), a developer of prescription pharmaceuticals that utilize currently marketed drugs or active pharmaceutical ingredients generally recognized as safe for use in therapeutic applications. The proceeds of the venture loan facility will be used for working capital purposes.

"We are pleased to provide NHP with a venture loan facility which will support its development of proprietary prescription pharmaceuticals," stated Gerald A. Michaud , President of Horizon. "NHP continues to achieve important strides in developing products for patients with a higher risk for secondary strokes or acute cardiac events. Based on the company's impressive product pipeline and experienced, well-respected management team, NHP represents a strong addition to Horizon's high-quality investment portfolio."

"Horizon's $2 million venture loan facility provides NHP with the right capital structure and the timely liquidity to continue to execute our product development and FDA registration plans," stated Patrick P. Fourteau, NHP's President & CEO. Harry H. Penner, Jr. , NHP's Executive Chairman, added, "The responsiveness and flexibility of the Horizon team resulted in a seamless process from initial contact to funding and a very positive business experience. It's gratifying to have Horizon, a Connecticut-based company like our own, as a financial partner."

About Horizon Technology Finance
Horizon Technology Finance Corporation is a business development company that provides secured loans to development-stage companies backed by established venture capital and private equity firms within the technology, life science, healthcare information and services, and clean-tech industries. The investment objective of Horizon Technology Finance is to maximize total risk-adjusted returns by generating current income from a portfolio of directly originated secured loans as well as capital appreciation from warrants to purchase the equity of portfolio companies. Headquartered in Farmington, Connecticut, with regional offices in Walnut Creek, California and Reston, Virginia, the Company is externally managed by its investment advisor, Horizon Technology Finance Management LLC. Horizon's common stock trades on the NASDAQ Global Select Market under the ticker symbol, "HRZN." In addition, the Company's 7.375% Senior Notes due 2019 trade on the New York Stock Exchange under the ticker symbol "HTF." To learn more, please visit www.horizontechnologyfinancecorp.com.

About New Haven Pharmaceuticals
New Haven Pharmaceuticals Inc. (NHP) is a specialty pharmaceutical company developing proprietary prescription drug products based on proprietary controlled-release technologies, as well as intellectual property licensed from Yale University, which will enable optimal dosing, safety, efficacy and patient convenience. For more information on NHP, please visit www.newhavenpharma.com, or contact Harry H. Penner, Jr. , Executive Chairman at (203) 676-3676, or email at hpenner@newhavenpharma.com.

Forward-Looking Statements
Statements included herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance, condition or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in our filings with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.Contact: Horizon Technology Finance CorporationInvestor Relations and Media Contacts:Christopher M. MathieuThe IGB Group Chief Financial OfficerMichael Cimini / Leon Berman(860) 676-8653(212) 477-8261 / (212) 477-8438chris@horizontechfinance.commcimini@igbir.com / lberman@igbir.com


'/>"/>
SOURCE Horizon Technology Finance Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Future Horizons in the Global Orthopedics Market
2. Horizon Pharma Announces Issuance of U.S. Patent Covering RAYOS (delayed-release prednisone)
3. 110+ Health Care Providers Announce Plans To Use Advanced Medical Records Technology To Improve Care For Thousands Of Denver-Area Patients
4. Memorial Hospital of Lafayette County Boosts Patient Safety with Expanded Use of Capnography Technology
5. TriMix Laboratories Announces New TriMix-gel Partnership with KRS Global Biotechnology
6. Endexx to attend NAMA Spring Expo for Medical Marijuana Technology Solutions
7. Creabilis Awarded Prestigious European Commission FP7 Grant to Further Develop its LSE Topical-by-Design Technology
8. iBio Passes Commercial Technology Transfer Milestone
9. Sanovas Launches Next Generation Surgical Imaging Technology
10. George Rosenkranz to Receive 2013 Biotechnology Heritage Award
11. Besins Healthcare, Shin Nippon Biomedical Laboratories, Ltd Announce Delivery Technology Licensing Agreement for Intranasal Progesterone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 2016 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, announced ... 2016 conference, presented by Joseph Gunnar & Co. ... New York . Nadav Kidron , CEO of ... Presentation Details:   PIONEERS 2016, presented ...
(Date:4/28/2016)... 2016 New market research ... a report that provides an overview of the ... by identifying new targets and MOAs to produce ... discussed in this H1 2016 Osteoarthritis Pipeline report ... Inc., Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, ...
(Date:4/27/2016)... 27, 2016   ... in Recurring Consumable Sales  Clinical sales grow ... Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the ... for the first quarter ended March 31, 2016 and ... of its commercial strategy. First Quarter 2016 ...
Breaking Medicine Technology:
(Date:5/2/2016)... , ... May 02, 2016 , ... ... website to help consumers better understand life insurance throughout various life stages. , ... an easy-to-use life insurance needs calculator and content specific to the times when ...
(Date:5/2/2016)... ... May 02, 2016 , ... WestHarbor Growth Partners, a growth, ... release of Grow Healthy Vending’s newly revamped brand campaign. Grow Healthy Vending ... vending providers in North America with locations across the United States as well ...
(Date:5/2/2016)... Naperville, Illinois (PRWEB) , ... May 02, 2016 , ... ... our modernized mail back service. MedPro now offers its mail back service for ... this offer; we are now able to provide service to all of the clients ...
(Date:5/2/2016)... (PRWEB) , ... May 02, 2016 , ... Dr. Rassouli, ... dental health and cognitive decline. According to the research, which was published in the ... degree of cognitive decline, and about 5.4 million Americans have Alzheimer’s disease. The study ...
(Date:5/2/2016)... , ... May 02, 2016 , ... According to an ... one in four girls are sexually abused before the age of 18. Of those ... to tell her story and others. , In her new book, Lyah! Lyah! ...
Breaking Medicine News(10 mins):